We are experiencing some temporary issues. The market data on this page are currently delayed. Please bear with us as we address this and restore your personalized lists.

CRIS
Curis, Inc.
NasdaqGM
People also watch : ARQL CERS ARRY AGEN CYTR
1.68 -0.06 (-3.45%)

After hours: 1.68-0.00 (-0.02%) as of 4:46 PM EDT

Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Prev Close 1.74
Open 1.73
Bid 1.57 x 100
Ask 1.85 x 1500
52wk Range 1.25 - 3.21
Day's Range 1.68 - 1.77
Volume 257,370
Avg Vol (3m) 422,980
As of 4:00 PM EDT. Market closed.
  • Curis (CRIS) in Focus: Stock Adds 5.7% in Session
    Zacks 2 days ago

    Curis (CRIS) in Focus: Stock Adds 5.7% in Session

    Curis, Inc. (CRIS) was a big mover last session, as the company saw its shares rise roughly 6% on the day.

  • Capital Cube 10 days ago

    ETF’s with exposure to Curis, Inc. : July 19, 2016

    Click here to see latest analysis*Disclaimer : This is as of previous day’s closeETF’s with exposure to Curis, Inc.Here are 5 ETF’s with the largest exposure to CRIS-US. Comparing the performance and risk of Curis, Inc. with the ETF’s that have exposure to it gives us some ETF choices that could give us similar returns […] (Read more...) The post ETF’s with exposure to Curis, Inc. : July 19, 2016 appeared first on CapitalCube.

  • American City Business Journals last month

    What’s so ‘groundbreaking’ about Curis’ new cancer drug that just began human trials?

    The field of so-called immuno-oncology drugs — those that enhance the immune system’s ability to fight cancer — has been a noisy one lately, with dozens of companies aiming to develop them after the U.S. approval of the first two in 2014. Opdivo, the Bristol-Meyer Squibb (BMY) drug for melanoma, lung and renal cancer, is expected to generate about $2.8 billion this year. Both are fruition of years of research into a new way of fighting cancer that’s intended to enhance existing cancer drugs.

  • Capital Cube 2 months ago

    ETF’s with exposure to Curis, Inc. : June 8, 2016

    Click here to see latest analysis*Disclaimer : This is as of previous day’s closeETF’s with exposure to Curis, Inc.Here are 5 ETF’s with the largest exposure to CRIS-US. Comparing the performance and risk of Curis, Inc. with the ETF’s that have exposure to it gives us some ETF choices that could give us similar returns […] (Read more...) The post ETF’s with exposure to Curis, Inc. : June 8, 2016 appeared first on CapitalCube.

  • Curis, Inc. :CRIS-US: Earnings Analysis: Q1, 2016 By the Numbers
    Capital Cube 2 months ago

    Curis, Inc. :CRIS-US: Earnings Analysis: Q1, 2016 By the Numbers

    Click here to see latest analysisCuris, Inc. reports financial results for the quarter ended March 31, 2016.We analyze the earnings along side the following peers of Curis, Inc. – Exelixis, Inc., Infinity Pharmaceuticals, Inc., Emergent BioSolutions Inc., Bristol-Myers Squibb Company, Spectrum Pharmaceuticals, Inc., Celldex Therapeutics, Inc., Pfizer Inc., Celgene Corporation and Synta Pharmaceuticals Corp. (EXEL-US, […] (Read more...) The post Curis, Inc. :CRIS-US: Earnings Analysis: Q1, 2016 By the Numbers appeared first on CapitalCube.

  • Thomson Reuters StreetEvents 3 months ago

    Edited Transcript of CRIS earnings conference call or presentation 9-May-16 12:30pm GMT

    Q1 2016 Curis Inc Earnings Call

  • Associated Press 3 months ago

    Curis reports 1Q loss

    The Lexington, Massachusetts-based company said it had a loss of 7 cents per share. The results topped Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research ...

  • Capital Cube 4 months ago

    ETF’s with exposure to Curis, Inc. : April 5, 2016

    Click here to see latest analysis*Disclaimer : This is as of previous day’s closeETF’s with exposure to Curis, Inc.Here are 5 ETF’s with the largest exposure to CRIS-US. Comparing the performance and risk of Curis, Inc. with the ETF’s that have exposure to it gives us some ETF choices that could give us similar returns […] (Read more...) The post ETF’s with exposure to Curis, Inc. : April 5, 2016 appeared first on CapitalCube.

  • Curis, Inc. :CRIS-US: Earnings Analysis: 2015 By the Numbers
    Capital Cube 5 months ago

    Curis, Inc. :CRIS-US: Earnings Analysis: 2015 By the Numbers

    Click here to see latest analysisCuris, Inc. reports financial results for the year ended December 31, 2015.We analyze the earnings along side the following peers of Curis, Inc. – Exelixis, Inc., Infinity Pharmaceuticals, Inc., Emergent BioSolutions Inc., Bristol-Myers Squibb Company, Spectrum Pharmaceuticals, Inc., Celldex Therapeutics, Inc., Pfizer Inc. and Celgene Corporation (EXEL-US, INFI-US, EBS-US, BMY-US, […] (Read more...) The post Curis, Inc. :CRIS-US: Earnings Analysis: 2015 By the Numbers appeared first on CapitalCube.

  • Thomson Reuters StreetEvents 5 months ago

    Edited Transcript of CRIS earnings conference call or presentation 29-Feb-16 1:30pm GMT

    Q4 2015 Curis Inc Earnings Call